Immunotech Biopharm Ltd (HKG:6978)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.450
+0.090 (3.81%)
At close: Mar 10, 2026

Immunotech Biopharm Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2018
Cash & Equivalents
21.0546.9652.1658.45353.34845.39
Upgrade
Trading Asset Securities
-10.54124.8121.01--
Upgrade
Cash & Short-Term Investments
21.0557.49176.9779.46353.34845.39
Upgrade
Cash Growth
-85.51%-67.51%122.72%-77.51%-58.20%199.52%
Upgrade
Other Receivables
-0.1----
Upgrade
Receivables
-0.1----
Upgrade
Inventory
5.425.544.927.2110.873.98
Upgrade
Other Current Assets
14.2924.363231.4447.9934.36
Upgrade
Total Current Assets
40.7687.49213.89118.11412.2883.72
Upgrade
Property, Plant & Equipment
424.46451.6500.76527.25426.59154.49
Upgrade
Long-Term Investments
--46.36140.18163.18131.97
Upgrade
Other Intangible Assets
18.5719.5541.8842.4914.257.37
Upgrade
Long-Term Deferred Charges
0.130.210.460.720.981.23
Upgrade
Other Long-Term Assets
4.985.1842.9250.6980.531.44
Upgrade
Total Assets
488.9564.04846.28879.441,0981,210
Upgrade
Accounts Payable
40.3533.6146.7637.3932.155.84
Upgrade
Accrued Expenses
172121.6527.1722.245.76
Upgrade
Current Portion of Long-Term Debt
318.59268.1326.84---
Upgrade
Current Portion of Leases
30.2427.4524.6826.0620.217.2
Upgrade
Current Income Taxes Payable
-0.96----
Upgrade
Current Unearned Revenue
1.471.781.854.365.194.25
Upgrade
Other Current Liabilities
88.8977.31108.5113.49100.318.57
Upgrade
Total Current Liabilities
496.54430.21530.28208.47180.131.62
Upgrade
Long-Term Debt
---1--
Upgrade
Long-Term Leases
81.589.02105.66122.7590.8543.86
Upgrade
Long-Term Unearned Revenue
56.3561.2739.4640.843.565.91
Upgrade
Total Liabilities
634.38580.5675.39373.07274.5181.38
Upgrade
Common Stock
3.583.583.583.583.583.58
Upgrade
Additional Paid-In Capital
1,4021,4021,4021,4021,4021,402
Upgrade
Retained Earnings
-1,934-1,805-1,618-1,283-965.22-610.99
Upgrade
Comprehensive Income & Other
385.69385.69385.69385.69381.4332.46
Upgrade
Total Common Equity
-142.4-13.3173.62508.44822.261,128
Upgrade
Minority Interest
-3.09-3.16-2.73-2.070.921.31
Upgrade
Shareholders' Equity
-145.49-16.45170.89506.37823.181,129
Upgrade
Total Liabilities & Equity
488.9564.04846.28879.441,0981,210
Upgrade
Total Debt
430.32384.56457.17149.81111.0551.06
Upgrade
Net Cash (Debt)
-409.27-327.07-280.2-70.35242.29794.33
Upgrade
Net Cash Growth
-----69.50%226.55%
Upgrade
Net Cash Per Share
-0.80-0.64-0.54-0.140.471.79
Upgrade
Filing Date Shares Outstanding
514.58514.58514.58514.58514.58514.58
Upgrade
Total Common Shares Outstanding
514.58514.58514.58514.58514.58514.58
Upgrade
Working Capital
-455.78-342.71-316.38-90.36232.1852.11
Upgrade
Book Value Per Share
-0.28-0.030.340.991.602.19
Upgrade
Tangible Book Value
-160.97-32.85131.73465.95808.011,120
Upgrade
Tangible Book Value Per Share
-0.31-0.060.260.911.572.18
Upgrade
Land
-83.9283.9283.9263.0550.15
Upgrade
Machinery
-153.36149.5386.176.541.34
Upgrade
Construction In Progress
-113.42107.65208.53151.852.5
Upgrade
Leasehold Improvements
-121.83121.8356.6956.2528.99
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.